Neurological Biomarkers Market Size, Share & Trends Report

Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer’s, Parkinson’s, Multiple Sclerosis, Autism), By Type, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-3-68038-823-7
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2022
  • Industry: Healthcare

Research Methodology

A three-pronged approach was followed for deducing the neurological biomarkers market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for neurological biomarkers market to gather the most reliable and current information possible.

  • We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
  • We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
  • We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
  • We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
  • We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of neurological biomarkers market data depending on the type of information we’re trying to uncover in our research.

  • Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

  • Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

  • Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

  • Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

  • Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

  • Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

  • This step also entails the finalization of the report scope and data representation pattern.

  • Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Neurological Biomarkers Market Categorization:

The neurological biomarkers market was categorized into four segments, namely type (Genomic, Proteomic, Metabolomic, Imaging), application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder), end-use (Hospital & Hospital Laboratories, Independent clinical diagnostic centers, Research Organizations and Others), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The neurological biomarkers market was segmented into type, application, end-use, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

  • Demand estimation of each product across countries/regions summed up to from the total market.

  • Variable analysis for demand forecast.

  • Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

  • Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

  • Used extensively for new product forecasting or analyzing penetration levels.

  • Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

  • Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

  • This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The neurological biomarkers market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway; India; China; Japan; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; Saudi Arabia; UAE; South Africa; Kuwait

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Neurological biomarkers market companies & financials:

The neurological biomarkers market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

  • Abbott - Abbott has a presence in more than 150 countries with research, manufacturing, sales, and distribution facilities. Its pharmaceuticals segment offers generic medicines for pain, fever, migraine, inflammation, pancreatic disorders, & hypertension; cardiovascular & metabolic products; and vaccines. The diagnostic segment offers reagents and tests for various applications. The company’s diagnostics portfolio includes technologies such as polymerase chain reaction, fluorescence in situ hybridization, and DNA & RNA sequencing.
  • Johnson & Johnson Services, Inc. - Johnson & Johnson Services, Inc. has over 250 operating units in more than 60 countries. It operates via three business units: consumer healthcare, pharmaceuticals, and medical devices. The consumer healthcare business unit has seven key franchises—nutritional products, skin & hair care, wound care, topical & over-the-counter drugs, oral health care, women’s health, and baby care. Janssen Pharmaceuticals, Inc.—a subsidiary of the company—is involved in the production of pharmaceutical and consumer products. The pharmaceuticals division consists of an array of drugs for neurological conditions, cancer, pain, and autoimmune diseases.
  • Bio-Rad Laboratories, Inc. - Bio-Rad Laboratories, Inc. manufactures systems & products used in separating complex biological and chemical materials as well as analyzing, identifying, and purifying their respective components. The company works in two segments: clinical diagnostics and life sciences. In the clinical diagnostics segment, it designs, manufactures, supports, and sells informatics systems, test systems, quality controls, & test kits. These products serve clinical laboratories in the global market. Similarly, the life sciences segment is employed in the creation and discovery of tools required in biological processes. The company manufactures reagents, apparatus, and laboratory instruments used in the process of biopharmaceutical production, research techniques, & food testing regimes.
  • Alseres Pharmaceuticals, Inc. - Alseres Pharmaceuticals, Inc. is a biotechnology company that focuses on the development of therapeutic and diagnostic products for neurological disorders. Its lead product candidate is Altopane, which is used as a molecular imaging agent for the diagnosis of neurological disorders such as dementia and Parkinson’s disease. The company focuses on entering into partnerships & collaborations for the development and commercialization of products.
  • Banyan Biomarkers, Inc. - Banyan Biomarkers, Inc. focuses on the development of diagnostic products for neurological diseases and injuries. The company was established by scientists from the University of Florida McKnight Brain Institute. With the support of research partners and the United States Department of Defense, the company developed a blood-based biomarker test by utilizing Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C- terminal Hydrolase-L1 (UCH-L1).
  • Rules-Based Medicine - Rules-Based Medicine, a Q2 Solutions company, is a multiplexed immunoassay testing laboratory that provides comprehensive biomarker services. Q2 solution is a wholly owned subsidiary and laboratory division of IQVIA engaged in providing genomics, vaccines, flow cytometry, immunoassay, bioanalytical, and companion diagnostic services. The company earned CLIA-accredited certification from COLA and is capable of supporting Good Laboratory Practices studies (GLP).
  • Thermo Fisher Scientific, Inc. - Thermo Fisher Scientific, Inc. manufactures and supplies scientific equipment, analytical instruments, and other laboratory equipment worldwide. The company’s operations are divided into pharmaceutical & biotechnology, industrial & applied research, diagnostics & healthcare, and academic & government. It provides chromatographs, Erlenmeyer flasks, gene sequencers & spectrometers, clinical analytical tools, and diagnostic testing products. The company serves more than 400,000 customers globally through various brands, including Applied Biosystem, Fisher Scientific, Thermo Scientific, Unity Lab Services, and Invitrogen. Its major products include molecular biology reagents, instruments, antibodies, protein biology reagents, and cell imaging & analysis instruments.
  • DiaGenic ASA - DiaGenic ASA focuses on the development of blood-based assays, which help in early diagnosis of Alzheimer’s disease and breast cancer. It focuses on the development of companion diagnostics for drug candidates. The company provides biomarkers as per European regulatory standards.
  • Merck & Co., Inc. - Merck & Co., Inc. is the parent company of Merck KGaA and is involved in the discovery, development, manufacturing, and commercialization of branded, prescription, & OTC pharmaceuticals, vaccines, and consumer care products for human & animal healthcare markets. The company offers healthcare solutions through prescription medicines, vaccines, therapeutic & preventive agents, biologic therapies, and animal health products. Key clients of the company include wholesalers & retailers, hospitals, government agencies, managed healthcare providers, and veterinarians.
  • Quanterix - Quanterix focuses on the development of therapeutics and diagnostics for therapy areas such as neurology, cardiology, oncology, infectious diseases, & inflammation. The company develops its product portfolio by utilizing its proprietary technology platform, Simoa. Furthermore, the company provides fully automated instruments for running tests performed through biomarkers. The company completed the acquisition of UmanDiagnostics AB and Aushon Biosystems, Inc. in August 2019 and January 2018, respectively.

Value chain-based sizing & forecasting

Supply Side Estimates

  • Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

  • Segment revenue determination via variable analysis and penetration modeling.

  • Competitive benchmarking to identify market leaders and their collective revenue shares.

  • Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

  • Identifying parent markets and ancillary markets

  • Segment penetration analysis to obtain pertinent

  • revenue/volume

  • Heuristic forecasting with the help of subject matter experts

  • Forecasting via variable analysis

Neurological Biomarkers Market Report Objectives:

  • Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

  • Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

  • Understanding market estimates and forecasts (with the base year as 2023, historic information from 2018 - 2022, and forecast from 2024 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Neurological Biomarkers Market Report Assumptions:

  • The report provides market value for the base year 2023 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

  • The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

  • We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

  • All market estimates and forecasts have been validated through primary interviews with the key industry participants.

  • Inflation has not been accounted for to estimate and forecast the market.

  • Numbers may not add up due to rounding off.

  • Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

  • Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

  • Latin America includes Central American countries and the South American continent

  • Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

  • Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

  • Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.

What questions do you have? Get quick response from our industry experts. Request a Free Consultation



This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.



We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon